Daniella Magen

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton et al. · New England Journal of Medicine · 2021 · 469 citations · Full text

Mutations in DHDPSL Are Responsible For Primary Hyperoxaluria Type III

Ruth Belostotsky, Eric Seboun, Gregory H. Idelson et al. · The American Journal of Human Genetics · 2010 · 227 citations · Full text

Dhdpsl Are Responsible, Genetic Disorder, Genetics +7

Mitochondrial Hsp60 Chaperonopathy Causes an Autosomal-Recessive Neurodegenerative Disorder Linked to Brain Hypomyelination and Leukodystrophy

Daniella Magen, Costa Georgopoulos, Peter Bross et al. · The American Journal of Human Genetics · 2008 · 210 citations · Full text

Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Alzheimer's Disease +10

A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria

Daniella Magen, Eli Sprecher, Israel Zelikovic et al. · Kidney International · 2004 · 115 citations · Full text

Urology, Renal Function, Medicine +9

Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial

Mini Michael, Jaap W. Groothoff, Hadas Shasha‐Lavsky et al. · American Journal of Kidney Diseases · 2022 · 79 citations · Full text